Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMETHYST trial of litifilimab in active cutaneous lupus erythematosus
CTR20234203Phase 3Active
- Sponsor
- Biogen
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of litifilimab in cutaneous lupus erythematosus (CLE), subacute cutaneous lupus erythematosus (SCLE), sponsored by Biogen. Started Aug 2024; status: active.
02
Drugs
litifilimab
03
Conditions
cutaneous lupus erythematosus (CLE)subacute cutaneous lupus erythematosus (SCLE)
Beyond the preview
Go deeper on CTR20234203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234203.